Market Overview

Prosensa Reports Initial Findings from Further Clinical Data Analyses of Drisapersen for Treatment of Duchenne Muscular Dystrophy


Prosensa Holding (NASDAQ: RNA) today announced initial findings from
further analyses from the aggregate data from the clinical
development program of drisapersen for the treatment of Duchenne
Muscular Dystrophy (DMD)."We are encouraged by these results that suggest
that treating earlier in the disease and treating longer shows a
delay in the progression of the disease," said Hans Schikan,
Prosensa's Chief Executive Officer. "These data encourage us to
engage patient groups, clinical experts and regulators to explore a
path forward for drisapersen, which includes the possibility of
re-dosing."Schikan will be presenting details of the
further data analyses at the 32nd Annual J.P. Morgan
Healthcare Conference in San Francisco on Thursday, January 16,
2014 at 10:00 AM Pacific Time. A live webcast of the presentation
can be accessed through the Investors & Media section of the
Prosensa corporate website at
 and will be archived for 90 days.With data from more than 300 patients Prosensa
has the largest clinical data set in DMD. In order to advance the
general understanding of DMD, Prosensa has also announced that it
will make certain data from the drisapersen clinical program
available to the scientific community. In addition it has initiated

See full press release

Posted-In: News Guidance Contracts FDA Management Global


Related Articles (RNA)

View Comments and Join the Discussion!

UPDATE: Canaccord Genuity Lowers Nu Skin Rating, Stock Plummets 21% Upon Operation Probe in China

Apple Agrees to $32 Million Settlement with FTC